Cytokine-based therapies hold immense promise, but their development has been anything but simple. From early breakthroughs to unforeseen hurdles, the field has faced complex challenges in safety, efficacy, and clinical translation. Rather than seeing these obstacles as setbacks, the cytokine community is coming together to understand, refine, and innovate – turning challenges into opportunities together.
Join the 6th Cytokine-Based Drug Development Summit where the most influential leaders from Candel, Deka Biosciences, Regeneron, Sanofi, ModeX, OSE, and more come together to navigate the key translational and therapeutic index challenges —from overcoming systemic toxicities and improving specificity to engineering next-generation cytokine therapeutics with pro-drug, pulsed, targeted, and multi-specific immunomodulation strategies.
Take part in intimate discussions with world-class insights from interactive workshops, roundtable discussion, and presentations to navigate the complexities of cytokine therapies and shape the future of immunotherapy.
At this pivotal time for cytokine drug developers – join us as we drive innovation and help break down barriers with systemic toxicity through improving specificity and delivery of cytokine-based drugs!
2025 Cytokine Trailblazers Include:
“After decades of research into the potential of cytokines to elicit antitumor immune responses, checkpoint inhibition appears to have made room for a new coming of age for cytokine therapy. It’s exciting to see the development of new technologies that can more precisely leverage the power and beauty of cytokine biology in this new era of cancer immunotherapy.”
Bridget O’Keeffe
Vice President Clinical Development
“This meeting brings together leaders in cytokine biology, therapeutic design, and immune oncology to collectively advance the development of targeted and effective cancer drugs.”
Jamie Spangler
Assistant Professor
Johns Hopkins University
